SEATTLE--(BUSINESS WIRE)-- Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company focused on discovering and developing novel therapeutics to treat the progression of sight-threatening ophthalmic diseases, today announced that Brian ... CNBC, 1 month ago
Acucela Announces That Brian OCallaghan Will Assume the Role of CEO; Ryo Kubota, M.D., Ph.D., to Remain Chairman of the Board - RCL Advisors, 1 month ago
Acucela : Announces That Brian O'Callaghan Will Assume the Role of CEO; Ryo Kubota, M.D., Ph.D., to Remain Chairman of the Board - 4 Traders, 1 month ago
Global Markets Direct's, 'Retinopathy Of Prematurity - Pipeline Review, H2 2014', provides an overview of the Retinopathy Of Prematurity's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ...Tamar Securities, 2 months ago
Research and Markets has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2014" report to its offerings. In a release, Research and Markets noted that report highlights include: This report provides comprehensive ...Individual.com, 2 months ago
on your WebpageAdd Widget >Get your members hooked!